| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | IGM; IMD3; TRAP; gp39; CD154; CD40L; HIGM1; T-BAM; TNFSF5; hCD40L |
| WB Predicted band size | 29 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human CD40LG |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CD40LG抗体的3篇文献示例(内容为虚构，仅供参考)：
1. **文献名称**：《抗CD40L单克隆抗体在系统性红斑狼疮模型中的治疗作用》
**作者**：Smith A, et al.
**摘要**：研究通过小鼠模型评估抗CD40L抗体对SLE的治疗效果，发现其能抑制自身抗体产生并减轻肾脏炎症，提示靶向CD40/CD40L通路可能成为自身免疫疾病的新策略。
2. **文献名称**：《CD40LG阻断抗体增强PD-1抑制剂在实体瘤中的协同效应》
**作者**：Zhang Y, et al.
**摘要**：该研究探索抗CD40L抗体与PD-1抑制剂联用对黑色素瘤的作用，结果显示联合疗法显著提升T细胞活性及肿瘤消退率，表明靶向共刺激通路可优化癌症免疫治疗。
3. **文献名称**：《抗CD40L抗体预防移植物抗宿主病的机制研究》
**作者**：Tanaka K, et al.
**摘要**：在异基因造血干细胞移植模型中，抗CD40L抗体通过抑制T细胞与抗原呈递细胞的相互作用，降低GVHD严重程度，为临床移植免疫调节提供理论支持。
(注：以上文献及作者为模拟示例，实际引用需查询PubMed、Web of Science等数据库。)
**Background of CD40LG Antibodies**
CD40 ligand (CD40LG), a member of the tumor necrosis factor (TNF) superfamily, is a transmembrane protein primarily expressed on activated T cells. It interacts with CD40. a receptor on B cells, dendritic cells, and other antigen-presenting cells, playing a pivotal role in adaptive immunity. This interaction triggers signaling pathways (e.g., NF-κB, MAPK) critical for B-cell activation, antibody class switching, and T-cell priming. Dysregulation of CD40-CD40LG signaling is implicated in autoimmune diseases (e.g., lupus, rheumatoid arthritis), atherosclerosis, and cancer.
CD40LG-targeting antibodies are designed to modulate this pathway. Antagonistic antibodies block CD40LG-CD40 binding, suppressing overactive immune responses in autoimmune conditions or preventing transplant rejection. Conversely, agonistic antibodies mimicking CD40LG activity enhance anti-tumor immunity by activating dendritic cells and promoting cytotoxic T-cell responses.
Early therapeutic anti-CD40LG antibodies faced challenges, including thromboembolic events linked to platelet CD40LG expression. Newer agents, such as fragment antigen-binding (Fab) variants or engineered non-Fc-binding antibodies, aim to improve safety. Clinical trials explore their efficacy in diseases like lupus, multiple sclerosis, and cancers. Research also focuses on bispecific antibodies combining CD40LG targeting with other immune checkpoints. Despite hurdles, CD40LG antibodies represent promising tools for precision immunotherapy.
×
